Odyssey Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ODYY research report →
Price Chart
About the company
Odyssey Health, Inc. operates as a medical enterprise, primarily focused on the innovation and development of diverse healthcare products. Its current portfolio encompasses CardioMap, an advanced device for cardiac monitoring and screening, alongside the "Save A Life" line of devices engineered for choking emergencies.
- CEO
- Joseph Michael Redmond
- IPO
- 2021
- Employees
- 2
- HQ
- Las Vegas, NV, US
Get TickerSpark's AI analysis on ODYY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $807.75K
- P/E
- -0.24
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -0.09
- EV/EBITDA
- 17.94
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 41.46%
- ROIC
- 13.19%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,020,753
- Net Income
- $-1,742,691-92.4%
- EPS
- $-0.02-78.5%
- OCF Growth
- +71.4%
- FCF Growth
- +71.4%
- 52W High
- $0.13
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.03
- Beta
- -1.45
- RSI (14)
- 42
- Avg Volume
- 135.15K
No earnings-call transcripts are available for ODYY yet.
- Free Float
- 84.3%
- Shares Outstanding
- 100.97M
- Float Shares
- 85.13M
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 28, 24 | FARRELL CHRISTINE | other | 500,000 |
| Jun 28, 24 | RICHARDSON RICKY | other | 300,000 |
| Jun 28, 24 | Casey Jerome H | other | 300,000 |
| Jun 28, 24 | REDMOND J MICHAEL | other | 500,000 |
| Jun 28, 24 | Gironda Gregory W | other | 250,000 |
| Jan 16, 24 | Gironda Gregory W | other | 37,500 |
| Jan 16, 24 | Emerson Erik C. | other | 37,500 |
| Jan 10, 24 | GANDOLFO JOHN P | other | 1,500,000 |
| Jan 10, 24 | GANDOLFO JOHN P | sell | 1,500,000 |
| Dec 29, 23 | Emerson Erik C. | other | 200,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ODYY coverage
Recent articles, reports, and earnings notes.
No research on ODYY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ODYY report →Head-To-Head Review: Odyssey Health (OTCMKTS:ODYY) & Enovis (NYSE:ENOV)
defenseworld.net · Aug 13
Odyssey Health, Inc. Secures Exclusive Global Distribution Rights for BreastCheck™ to Drive Recurring Revenue Growth
prnewswire.com · Apr 22
Odyssey Health, Inc. (OTCMKTS:ODYY) Short Interest Update
defenseworld.net · Feb 12
Odyssey Health, Inc. Secures Multi-Million-Dollar, Nine-Year Service Contract and Financing Facility for Up to $25 Million
globenewswire.com · Nov 19
Odyssey Health, Inc., Enters the $26 Billion Breast Cancer Marketplace
globenewswire.com · Oct 16
Odyssey Health, Inc. to Advance Development of its Save A Life Choking Rescue Device
globenewswire.com · Aug 26
Odyssey Health, Inc. Strengthens Balance Sheet with $8.7 Million in Net Equity
accesswire.com · Mar 27
Odyssey Health Closes Asset Sale of its Neurological Drug Technology Pipeline Including Concussion Drug Candidate with Oragenics, Inc.
accesswire.com · Jan 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.